175 related articles for article (PubMed ID: 31592652)
1. Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
Peng X; Gao J; Yuan Y; Liu H; Lei W; Li S; Zhang J; Wang S
Bioconjug Chem; 2019 Nov; 30(11):2828-2843. PubMed ID: 31592652
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Activated Anticancer Prodrug for Bioimaging, Tracking Drug Release, and Anticancer Application.
Liu W; Liu H; Peng X; Zhou G; Liu D; Li S; Zhang J; Wang S
Bioconjug Chem; 2018 Oct; 29(10):3332-3343. PubMed ID: 30192132
[TBL] [Abstract][Full Text] [Related]
3.
Dong Y; Du P; Liu P
Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
5. An upconverting nanotheranostic agent activated by hypoxia combined with NIR irradiation for selective hypoxia imaging and tumour therapy.
Li H; Lei W; Wu J; Li S; Zhou G; Liu D; Yang X; Wang S; Li Z; Zhang J
J Mater Chem B; 2018 May; 6(18):2747-2757. PubMed ID: 32254227
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug: in vivo imaging and precise cancer treatment.
Kumar R; Han J; Lim HJ; Ren WX; Lim JY; Kim JH; Kim JS
J Am Chem Soc; 2014 Dec; 136(51):17836-43. PubMed ID: 25402959
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional Theranostic Liposomes Loaded with a Hypoxia-Activated Prodrug for Cascade-Activated Tumor Selective Combination Therapy.
Dai Y; Wang B; Sun Z; Cheng J; Zhao H; Wu K; Sun P; Shen Q; Li M; Fan Q
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39410-39423. PubMed ID: 31578854
[TBL] [Abstract][Full Text] [Related]
8. COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models.
Kim HS; Sharma A; Ren WX; Han J; Kim JS
Biomaterials; 2018 Dec; 185():63-72. PubMed ID: 30223141
[TBL] [Abstract][Full Text] [Related]
9. A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging.
Kong F; Liang Z; Luan D; Liu X; Xu K; Tang B
Anal Chem; 2016 Jun; 88(12):6450-6. PubMed ID: 27216623
[TBL] [Abstract][Full Text] [Related]
10. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
12. Floxuridine Oligomers Activated under Hypoxic Environment.
Morihiro K; Ishinabe T; Takatsu M; Osumi H; Osawa T; Okamoto A
J Am Chem Soc; 2021 Mar; 143(9):3340-3347. PubMed ID: 33648338
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.
Feng L; Cheng L; Dong Z; Tao D; Barnhart TE; Cai W; Chen M; Liu Z
ACS Nano; 2017 Jan; 11(1):927-937. PubMed ID: 28027442
[TBL] [Abstract][Full Text] [Related]
14. A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma.
Wang X; Chang Z; Nie X; Li Y; Hu Z; Ma J; Wang W; Song T; Zhou P; Wang H; Yuan Z
Nanomedicine; 2019 Jan; 15(1):153-163. PubMed ID: 30308299
[TBL] [Abstract][Full Text] [Related]
15. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
16. A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control.
Feng W; Gao C; Liu W; Ren H; Wang C; Ge K; Li S; Zhou G; Li H; Wang S; Jia G; Li Z; Zhang J
Chem Commun (Camb); 2016 Aug; 52(60):9434-7. PubMed ID: 27379361
[TBL] [Abstract][Full Text] [Related]
17. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
Wang B; Qi FZ; Chen P; Qian LM; Su HS; Wang Y; Wang CH; Hou YX; Zhang Q; Li D; Chen ZS; Zhang SH
Int J Biol Sci; 2024; 20(5):1634-1651. PubMed ID: 38481819
[No Abstract] [Full Text] [Related]
19. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
20. A photoactivated prodrug.
Wei Y; Yan Y; Pei D; Gong B
Bioorg Med Chem Lett; 1998 Sep; 8(18):2419-22. PubMed ID: 9873553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
